CLINICAL STUDIES
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial
The Paradigm Investigators
Manuscript received March 23, 1998;
revised manuscript received July 10, 1998,
accepted August 6, 1998.
Address for correspondence: Robert A. Harrington, MD, FACC, Duke Clinical Research Institute, 2024 West Main Street, Durham, NC 27705
Harri019{at}mc.duke.edu
Objectives. The trial was designed to assess the safety, pharmacodynamics and effects on reperfusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor lamifiban when given with thrombolysis to patients with ST segment elevation acute myocardial infarction.
Background. Studies of fibrinolytic agents in acute myocardial infarction have demonstrated a direct relationship between early complete reperfusion and survival. Blockade of the platelet GP IIb/IIIa receptor complex inhibits platelet aggregation and may speed reperfusion when given in conjunction with thrombolysis to patients with acute myocardial infarction.
Methods. Patients with ST segment elevation presenting within 12 h of symptom onset who were treated with either tissue-plasminogen activator or streptokinase were enrolled in this three-part Phase II dose exploration study. In Part A, all patients received the GP IIb/IIIa inhibitor lamifiban in an open-label, dose escalation scheme. Parts B and C were a randomized, double-blind comparison of a bolus plus 24-h infusion of lamifiban versus placebo with patients randomized in a 2:1 ratio. The goal was to identify a dose(s) of lamifiban that provided >85% adenosine diphosphate (ADP)-induced platelet aggregation inhibition. A composite of angiographic, continuous electrocardiographic and clinical markers of reperfusion was the primary efficacy end point, and bleeding was the primary safety end point.
Results. Platelet aggregation was inhibited by lamifiban in a dose-dependent manner with the highest doses exceeding 85% ADP-induced platelet aggregation inhibition. There was more bleeding associated with lamifiban (transfusions in 16.1% lamifiban-treated vs. 10.3% placebo-treated patients). Lamifiban induced more rapid reperfusion as measured by all continuous electrocardiographic (ECG) parameters.
Conclusions. Lamifiban given with thrombolytic therapy appears to be associated with more rapid and complete reperfusion than placebo. As expected in this small sample, there were no obvious clinical benefits to lamifiban over placebo. Reconciliation of ECG monitoring with clinical outcomes will require a larger, adequately powered clinical trial.
|
Abbreviations and Acronyms
| | ADP | = adenosine diphosphate | | GP | = glycoprotein | | PARADIGM | = Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction | | SK | = streptokinase | | TIMI | = Thrombolysis in Myocardial Infarction | | t-PA | = tissue-plasminogen activator | | TRAP | = thrombin receptor agonist peptide |
|
This article has been cited by other articles:
|
|
|
|
 
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol
Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials
JAMA,
April 13, 2005;
293(14):
1759 - 1765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Bhatia, G J Clesham, and D R Turner
Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction
J R Soc Med,
December 1, 2004;
97(12):
566 - 570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
549S - 575S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A Crouch, J. M Nappi, and K. I Cheang
Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome
Ann. Pharmacother.,
June 1, 2003;
37(6):
860 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Lincoff, R. M. Califf, F. Van de Werf, J. T. Willerson, H. D. White, P. W. Armstrong, V. Guetta, W. B. Gibler, J. S. Hochman, C. Bode, et al.
Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial
JAMA,
November 6, 2002;
288(17):
2130 - 2135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Baker Jr
Thrombolytic Therapy
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2002;
8(4):
291 - 314.
[PDF]
|
|
|
|
|
|
|
S. M. Inverso
Combination Glycoprotein IIb/IIIa Receptor Antagonists With Thrombolytics in Acute Myocardial Infarction
Journal of Pharmacy Practice,
August 1, 2002;
15(4):
344 - 355.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Barrabes, D. Garcia-Dorado, M. Mirabet, R.-M. Lidon, B. Soriano, M. Ruiz-Meana, P. Pizcueta, J. Blanco, Y. Puigfel, and J. Soler-Soler
Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs
J. Am. Coll. Cardiol.,
January 2, 2002;
39(1):
157 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. de Lemos and E. Braunwald
ST segment resolution as a tool for assessing the efficacy of reperfusion therapy
J. Am. Coll. Cardiol.,
November 1, 2001;
38(5):
1283 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Llevadot, R. P. Giugliano, and E. M. Antman
Bolus Fibrinolytic Therapy in Acute Myocardial Infarction
JAMA,
July 25, 2001;
286(4):
442 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.C. Herrmann, R.H. Li, and E.M. Ohman
Facilitated percutaneous coronary intervention: results from the SPEED trial
Eur. Heart J. Suppl.,
May 1, 2001;
3(suppl_A):
A26 - A34.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. T. Roe, E. M. Ohman, A. C. P. Maas, R. H. Christenson, K. W. Mahaffey, C. B. Granger, R. A. Harrington, R. M. Califf, and M. W. Krucoff
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
J. Am. Coll. Cardiol.,
January 1, 2001;
37(1):
9 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest,
January 1, 2001;
119
(2009):
253S - 277S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.W. Armstrong
Reperfusion synergism: will it be both sustained and safe?
Eur. Heart J.,
December 1, 2000;
21(23):
1913 - 1916.
[PDF]
|
|
|
|
|
|
|
D. P. Chew and D. J. Moliterno
A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
J. Am. Coll. Cardiol.,
December 1, 2000;
36(7):
2028 - 2035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wilcox
Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy
Eur. Heart J.,
September 2, 2000;
21(18):
1495 - 1497.
[PDF]
|
|
|
|
|
|
|
E Ronner, H.A.M van Kesteren, P Zijnen, E Altmann, P.G Molhoek, L.R van der Wieken, C.A Cuffie-Jackson, K.L Neuhaus, and M.L Simoons
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study
Eur. Heart J.,
September 2, 2000;
21(18):
1530 - 1536.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Verstraete
Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development
Circulation,
February 15, 2000;
101
(6):
e76 - e80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. B A Menown and A A J. Adgey
Improving reperfusion after myocardial infarction
BMJ,
December 11, 1999;
319(7224):
1513 - 1515.
[Full Text]
|
|
|
|
|
|
|
D. A. Vorchheimer, J. J. Badimon, and V. Fuster
Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease
JAMA,
April 21, 1999;
281(15):
1407 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
